---
title: "Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286252932.md"
description: "Wells Fargo analyst maintained a Buy rating on Alkermes today and set a price target of $44.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Wells Fargo, Alkermes also received a Buy from Robert W. Baird’s Luke Herrmann in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Alkermes (NASDAQ: ALKS)."
datetime: "2026-05-13T11:30:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286252932.md)
  - [en](https://longbridge.com/en/news/286252932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286252932.md)
---

# Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)

Wells Fargo analyst maintained a Buy rating on Alkermes today and set a price target of $44.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

In addition to Wells Fargo, Alkermes also received a Buy from Robert W. Baird’s Luke Herrmann in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Alkermes (NASDAQ: ALKS).

### Related Stocks

- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz](https://longbridge.com/en/news/286085128.md)
- [Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment](https://longbridge.com/en/news/286107593.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)
- [RBC Capital Sticks to Their Buy Rating for Brambles  (BMBLF)](https://longbridge.com/en/news/286848311.md)